CTOs on the Move

St. Joseph Children's Home

www.sjkids.org

 
We providing a continuum of care through our three programs: Foster Care and Adoption Program, Residential Treatment Program, and Child Development Center.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.sjkids.org
  • 2823, Frankfort Avenue
    Louisville, KY USA 40206
  • Phone: 502.893.0241

Executives

Name Title Contact Details

Similar Companies

Fulcrum Pharma Developments

Fulcrum Pharma Developments Inc. is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saluda Medical

Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed to maintain individualized, consistent therapy by precisely controlling spinal cord activation through real-time customization of waveforms on every evoked compound action potential (ECAP) at the same rate as the stimulation frequency (At stimulation frequency of 40 Hz, 40 adjustments are made each second, 3`5 million adjustments per day, and 1`2 billion adjustments per year)`

Immtech International

Immtech International, Inc. is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Summit Counseling Solutions

Summit Counseling Solutions is a mental health care provider that offers adolescent day treatment and intensive outpatient services.

PvP Biologics

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion. Affecting an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Many patients continue to report persistent symptoms despite adhering to a gluten-free diet. The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. We have corporate offices in San Diego and research laboratories in Seattle.